RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > In Focus: Alternative Approval Pathways for Drug Products

In Focus: Alternative Approval Pathways for Drug Products

Posted 01 April 2010

Developing new drugs and biologics is a lengthy and expensive process, often costing hundreds of millions of dollars and requiring up to 10 years. However, not all new products require similar investment of resources for approval by the US Food and Drug Administration. There are several regulatory pathways, some new and some that have existed for years, that could lead to regulatory approval in less time and with fewer financial and technical resources. This issue of Regulatory Focus addresses some of these alternative pathways. Although similar development pathways are available in many countries, in the US they are exceptionally advantageous due to a number of regulatory incentives.

 

© 2022 Regulatory Affairs Professionals Society.